Joseph, R. W. (2018). Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. The American Association for Cancer Research (AACR).
Chicago Style (17th ed.) CitationJoseph, R. W. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. The American Association for Cancer Research (AACR), 2018.
MLA (9th ed.) CitationJoseph, R. W. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. The American Association for Cancer Research (AACR), 2018.
Warning: These citations may not always be 100% accurate.